Ginkgo biloba extracts and cancer:: a research area in its infancy

被引:170
作者
DeFeudis, FV
Papadopoulos, V
Drieu, K
机构
[1] Inst Biosci, Westborough, MA USA
[2] Georgetown Univ, Med Ctr, Div Hormone Res, Dept Cell Biol, Washington, DC USA
[3] Georgetown Univ, Med Ctr, Div Hormone Res, Dept Pharmacol, Washington, DC USA
[4] Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC USA
[5] Beafour IPSEN Pharma, Paris, France
关键词
antioxidant; cancer; chemoprevention; gene expression; Ginkgo biloba; ginkgolide;
D O I
10.1046/j.1472-8206.2003.00156.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recent studies conducted with various molecular, cellular and whole animal models have revealed that leaf extracts of Ginkgo biloba may have anticancer (chemopreventive) properties that are related to their antioxidant, anti-angiogenic and gene-regulatory actions. The antioxidant and associated anti-lipoperoxidative effects of Ginkgo extracts appear to involve both their flavonoid and terpenoid constituents. The anti-angiogenic activity of the extracts may involve their antioxidant activity and their ability to inhibit both inducible and endothelial forms of nitric oxide synthase. With regard to gene expression, a Ginkgo extract and one of its terpenoid constituents, ginkgolide B, inhibited the proliferation of a highly aggressive human breast cancer cell line and xenografts of this cell line in nude mice. cDNA microarray analyses have shown that exposure of human breast cancer cells to a Ginkgo extract altered the expression of genes that are involved in the regulation of cell proliferation, cell differentiation or apoptosis, and that exposure of human bladder cancer cells to a Ginkgo extract produced an adaptive transcriptional response that augments antioxidant status and inhibits DNA damage. In humans, Ginkgo extracts inhibit the formation of radiation-induced (chromosome-damaging) clastogenic factors and ultraviolet light-induced oxidative stress - effects that may also be associated with anticancer activity. Flavonoid and terpenoid constituents of Ginkgo extracts may act in a complementary manner to inhibit several carcinogenesis-related processes, and therefore the total extracts may be required for producing optimal effects.
引用
收藏
页码:405 / 417
页数:13
相关论文
共 110 条
[11]   Inhibition of the multidrug resistance protein 1 (MRP1) by peptidomimetic glutathione-conjugate analogs [J].
Burg, D ;
Wielinga, P ;
Zelcer, N ;
Saeki, T ;
Mulder, GJ ;
Borst, P .
MOLECULAR PHARMACOLOGY, 2002, 62 (05) :1160-1166
[12]   Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1 [J].
Casagrande, F ;
Darbon, JM .
BIOCHEMICAL PHARMACOLOGY, 2001, 61 (10) :1205-1215
[13]  
CHATTERJEE SS, 1985, EFFECTS GINKGO BILOB, P5
[14]   Induction of heme oxygenase-1 by Ginkgo Biloba Extract but not its terpenoids partially mediated its protective effect against lysophosphatidylcholine-induced damage [J].
Chen, JX ;
Zeng, H ;
Chen, X ;
Su, CY ;
Lai, CC .
PHARMACOLOGICAL RESEARCH, 2001, 43 (01) :63-69
[15]   Inhibition by ginkgolides and bilobalide of the production of nitric oxide in macrophages (THP-1) but not in endothelial cells (HUVEC) [J].
Cheung, FL ;
Siow, YL ;
O, K .
BIOCHEMICAL PHARMACOLOGY, 2001, 61 (04) :503-510
[16]   Evidence for peroxynitrite-mediated modifications to p53 in human gliomas: Possible functional consequences [J].
Cobbs, CS ;
Samanta, M ;
Harkins, LE ;
Gillespie, GY ;
Merrick, BA ;
MacMillan-Crow, LA .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2001, 394 (02) :167-172
[17]  
COBBS CS, 1995, CANCER RES, V55, P727
[18]  
DEBY C, 1993, ADV GINKGO, V2, P13
[19]   EXCESS EDRF/NO, A POTENTIALLY DELETERIOUS CONDITION THAT MAY BE INVOLVED IN ACCELERATED ATHEROGENESIS AND OTHER CHRONIC DISEASE STATES [J].
DEFEUDIS, FV .
GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1995, 26 (04) :667-680
[20]  
DEFEUDIS FV, 1985, EFFECTS GINKGO BILOB, P17